 HAIKOU, China , Aug. 5, 2021 PRNewswire -- China Pharma Holdings, Inc. NYSE American: CPHI China Pharma, the Company or We, a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administrations NMPA approval. 